Currently, diagnosis of BIA-ALCL relies on imaging investigations of suspicious masses or effusions along with immunohistochemical analysis, cytology examination, and flow cytometry assessment where CD30 expression is often strongly observed.[21,22] Furthermore, although a case report has suggested the utilization of PET-CT for diagnosing and staging BIA-ALCL more accurately, there is currently insufficient empirical evidence to establish its feasibility at an evidence-based level.[23]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.